The FDA lists a supplement, dated 8 October, to Sandoz's abbreviated new drug application for tafluprost, the prostaglandin analogue eye drop used to lower intraocular pressure in glaucoma and ocular hypertension.
Supplements to generic applications usually cover manufacturing, labelling or packaging changes. The listing does not describe a new indication or a safety finding.
This has no direct effect on prescribing in India, where tafluprost availability depends on CDSCO approvals and local supply. Nothing in it changes how the drug should be used.
- No change to how tafluprost is prescribed or monitored
- The action is a supplement to a generic application, not a new approval or safety warning
- Tafluprost is one of several prostaglandin analogue options for first-line pressure lowering
Why it matters
It confirms continued generic supply activity for a first-line glaucoma drop.
Don't overread it
A licence supplement is not a new indication or a safety signal.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free